Skip to Content

Glyxambi (empagliflozin / linagliptin) Disease Interactions

There are 4 disease interactions with Glyxambi (empagliflozin / linagliptin):


DPP-4 inhibitors (Includes Glyxambi) ↔ pancreatitis

Severe Potential Hazard, Low plausibility. Applies to: Pancreatitis

There have been postmarketing reports of acute pancreatitis in patients taking DPP-4 inhibitors. These drugs should be used with caution in patients with a history of pancreatitis or pancreatic disease, although it is unknown if they are at increased risk. Patients should be observed for signs and symptoms of pancreatitis during treatment. If pancreatitis is suspected, treatment should be discontinued immediately and appropriate management should be initiated.


SGLT-2 inhibitors (Includes Glyxambi) ↔ renal dysfunction

Severe Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

The glucose lowering effects of SGLT-2 inhibitors is decreased in patients with worsening renal function. Additionally, SGLT-2 inhibitors increase serum creatinine and decrease eGFR. The elderly and patients with moderate renal impairment are at increased risk of further renal dysfunction. Renal function should be evaluated before treatment initiation and monitored regularly in these patients. The use of SGLT-2 inhibitors in patients with severe renal impairment, end stage renal dysfunction (ESRD), or undergoing dialysis is contraindicated. Based on its mechanism of action, SGLT-2 inhibitors are not expected to be effective in patients with this level of renal dysfunction.


SGLT-2 inhibitors (Includes Glyxambi) ↔ hyperlipidemia

Moderate Potential Hazard, Moderate plausibility. Applies to: Hyperlipidemia

There have been reports of dose-related increases in LDL cholesterol with the use of SGLT-2 inhibitors. Cholesterol levels should be monitored before and during treatment and appropriate therapy should be initiated if needed.


SGLT-2 inhibitors (Includes Glyxambi) ↔ Hypotension

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction, Hypotension

SGLT-2 inhibitors cause intravascular volume contraction and symptomatic hypotension may occur after treatment initiation especially in the elderly, in patients with impaired renal function, low systolic blood pressure, or using diuretics . Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.

Glyxambi (empagliflozin / linagliptin) drug interactions

There are 828 drug interactions with Glyxambi (empagliflozin / linagliptin)

Glyxambi (empagliflozin / linagliptin) alcohol/food interactions

There are 2 alcohol/food interactions with Glyxambi (empagliflozin / linagliptin)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.